Ginkgo Bioworks Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
DNA$12.37+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
6. Marketable Securities
- Marketable Securities
Investments in marketable securities, including those classified in cash and cash equivalents, are summarized as follows (in thousands):
| December 31, 2025 | ||||
|---|---|---|---|---|
| Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value | |
| U.S. Treasury securities | $117,919 | $171 | $(52) | $118,038 |
| Corporate bonds | 114,640 | 147 | (121) | 114,666 |
| Commercial paper | 4,079 | — | (19) | 4,060 |
| Marketable equity securities | — | — | — | 18,654 |
| Total marketable securities | $236,638 | $318 | $(192) | $255,418 |
The amortized cost and estimated fair value of marketable debt securities are summarized below by contractual maturity dates (in thousands):
| December 31, 2025 | ||
|---|---|---|
| Amortized cost | Fair value | |
| Due within one year | $205,540 | $205,617 |
| Due after one year through five years | 31,098 | 31,147 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.